DermBiont, Inc.

DermBiont, Inc.

Biotechnology Research 451 D St 20 employees ARQT
Employees
20
Contacts
2
Emails
2

DermBiont, Inc. Overview

Headquarters
451 D St
Website
dermbiont.com
Industry
Biotechnology Research
Employees
20
Founded
2017
Stock Symbol
ARQT
Funding
35.2M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About DermBiont, Inc.

DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.

DermBiont, Inc. Contact Details

People in AeroLeads
4
With contact data
2
Email contacts
2
50.0% coverage

DermBiont, Inc. Org Chart

Sample employees and titles
Name Title Contact
Daniel Geffken Founder and Managing Director
View
Nichola Eliovits
Email
Karl Beutner, M.d., Ph.d. CEO and Co-founder at Dermbiont, Inc.
View
Ravi Pandrapragada Senior Vice President of Development
Email

Employees by Management Level

Executive 4 profiles
Individual contributor 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 1 1 0
IT 1 1 0

DermBiont, Inc. Tech Stack

Data / AI 2 profiles

Compare Similar Companies to DermBiont, Inc.